In case of TSC1, this has already been done, as rapamycin (a drug inhibiting mTOR, which is in turn activated by TSC1/2) was used in numerous studies for AD/tauopathies, but with ambiguous results [257]. The gene discussed is TSC1; the disease is Alzheimer disease.